This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2
Bijan Soleymani
Corresponding Author
Ali Najafi
Corresponding Author
Ebrahim Barzegari
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
One of the strategies against the lack of data and short onset time of the ongoing COVID-19 disease is the use of computational methods in the field of drug and vaccine design. Though demanding experimental validations, these methods can greatly reduce the time and cost of the immunogenic development projects. In this protocol, we describe the use of various immunoinformatics tools to design a multi-epitope vaccine polypeptide with the highest potential for activating the human immune system against SARS-CoV-2. The initial epitope set was extracted from the whole set of viral structural proteins. Their potential non-toxic and non-allergenic T-cell and B-cell binding and cytokine inducing epitopes were then identified through a priori immunoinformatic prediction. Selected epitopes were bonded to each other with appropriate links. A suitable adjuvant was added to the N-terminus of the vaccine polypeptide sequence to increase its immunogenicity. Molecular modelling of the 3D structure of the vaccine polypeptide, docking, molecular dynamics simulations and free energy calculations were used to confirm stability and receptor affinity. Time taken to complete: 43 days.
Keywords
SARS-CoV-2, Multi-epitope Vaccine, Molecular Dynamics Simulations, Toll-like Receptor 3, Immunoinformatics
John Connaughton
commented on 12 December, 2020
no vaccine to early
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Dec, 2020
Community comments: 1
Metrics
Comments: 1
HTML Views: ...
Associated Publications
Learn more about our company.
This is a preprint. It has not completed peer review.
Method Article
Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2
Bijan Soleymani
Corresponding Author
Ali Najafi
Corresponding Author
Ebrahim Barzegari
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 02 Dec, 2020
Community comments: 1
Metrics
Comments: 1
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
One of the strategies against the lack of data and short onset time of the ongoing COVID-19 disease is the use of computational methods in the field of drug and vaccine design. Though demanding experimental validations, these methods can greatly reduce the time and cost of the immunogenic development projects. In this protocol, we describe the use of various immunoinformatics tools to design a multi-epitope vaccine polypeptide with the highest potential for activating the human immune system against SARS-CoV-2. The initial epitope set was extracted from the whole set of viral structural proteins. Their potential non-toxic and non-allergenic T-cell and B-cell binding and cytokine inducing epitopes were then identified through a priori immunoinformatic prediction. Selected epitopes were bonded to each other with appropriate links. A suitable adjuvant was added to the N-terminus of the vaccine polypeptide sequence to increase its immunogenicity. Molecular modelling of the 3D structure of the vaccine polypeptide, docking, molecular dynamics simulations and free energy calculations were used to confirm stability and receptor affinity. Time taken to complete: 43 days.
John Connaughton
commented on 12 December, 2020
no vaccine to early